Hormonal
Subcutaneous semaglutide 2.4 mg administered once weekly significantly reduces body weight and cardiometabolic risk factors (HbA1c, total cholesterol, systolic blood pressure) in East Asian adults with obesity compared to placebo, though it is associated with higher rates of adverse events.
For East Asian adults with obesity, once-weekly subcutaneous semaglutide (2.4 mg) combined with diet and exercise is a clinically effective treatment for significant body weight reduction and improvement in cardiometabolic risk factors like blood pressure and cholesterol. Patients should be aware that adverse events are more common than with placebo, but the clinical benefits are established.
The STEP 6 study established the clinical efficacy of subcutaneous semaglutide compared with placebo in the reduction of body weight and cardiometabolic risk factors [glycated hemoglobin (HbA1c), total cholesterol, and systolic blood pressure] among Japanese and South Korean people with obesity disease.
Why this rating
Based on a systematic review of randomized controlled trials (STEP 6), though limited to two specific studies with potential bias in indirect comparisons.
Source
Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment Comparison
Koutaro Yokote et al. · Advances in Therapy · 2024
DOI 10.1007/s12325-024-02941-7
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →